Melanoma in 2011: A new paradigm tumor for drug development

Nature Reviews Clinical Oncology

Volumn 9, Issue 2, 2012, Pages 74-76

  Eggermont, Alexander M M ^a   Robert, Caroline ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; B RAF KINASE; B RAF KINASE INHIBITOR; DACARBAZINE; IMATINIB; IPILIMUMAB; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PEGINTERFERON ALPHA2B; STEM CELL FACTOR; VEMURAFENIB;

ADVANCED CANCER; ARTHRALGIA; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; DRUG EFFICACY; DRUG SAFETY; FATIGUE; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; HUMAN; IMMUNOTHERAPY; KERATOACANTHOMA; MELANOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHOTOSENSITIVITY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RASH; REVIEW; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; UNSPECIFIED SIDE EFFECT;

CLINICAL TRIALS AS TOPIC; DRUG DESIGN; HISTORY, 21ST CENTURY; HUMANS; MELANOMA; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASM PROTEINS;

EID: 84856598992     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2011.201     Document Type: Review

References (10)

1. Flaherty, K. T. et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809-819 (2010).
2. Chapman, P. B. et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507-2516 (2011).
3. Infante, J. R. et al. Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436) [abstract]. J. Clin. Oncol. 29 (Suppl.), CRA8503J (2011).
4. Carvajal, R. D. et al. KIT as a therapeutic target in metastatic melanoma. JAMA. 305, 2327-2334 (2011).
5. Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711-723 (2010).
6. Robert, C. et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364, 2517-2526 (2011).
7. Hoos, A. et al. Improved endpoints for cancer immunotherapy trials. J. Natl Cancer Inst. 102, 1388-1397 (2010).
8. Green, D. R., Ferguson, T., Zitvogel, L. & Kroemer, G. Immunogenic and tolerogenic cell death. Nat. Rev. Immunol. 9, 353-363 (2009).
9. Brahmer, J. R. et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 28, 3167-3175 (2010).
10. Eggermont, A. M. et al. Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. Eur. J. Cancer. doi:10.1016/j.ejca.2011.09.028